Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-Gr-1 refers to a **rat monoclonal antibody (clone RB6-8C5)** that recognizes the murine Gr-1 antigen (also known as Ly6G/Ly6C), a 21-25 kDa glycosylphosphatidylinositol (GPI)-linked cell surface protein from the Ly-6 family. The antibody binds strongly to Ly6G and weakly to Ly6C, which are expressed on granulocytes, neutrophils, and—to a lesser extent—on monocytes and macrophages. **Anti-Gr-1 is used in preclinical mouse studies for depleting Gr-1+ myeloid cells (mainly neutrophils and subsets of myeloid-derived suppressor cells), to study the role of these cells in tumor immunity, autoimmunity, and inflammation.** The antibody does not target a human protein, is not an approved therapeutic, and is used strictly for research. Its mechanism involves antibody-mediated depletion of target cell populations via complement or Fc-mediated effector functions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-Gr-1.